Angiology

Company initiates COSTAR II pivotal drug-eluting stent clinical trial in U.S.

Published in Clinical Trials Week, June 27th, 2005

Conor Medsystems, Inc., (CONR), a developer of controlled vascular drug-delivery technologies, announced that the first patient has been enrolled in the company's COSTAR (cobalt chromium stent with antiproliferative for restenosis) II U.S. pivotal clinical trial.

The COSTAR II trial is designed to randomize approximately 1,700 patients at up to 75 U.S. sites and 15 international sites. Conor expects the data from this trial to support its application for U.S. regulatory approval of Conor's CoStar cobalt chromium paclitaxel-eluting stent. The first patient procedure was performed by Dean J. Kereiakes, MD, FACC, medical director of The Heart Center of Greater Cincinnati...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2005-06-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry